FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT C	OF CHANGES	IN BENEFICIAL	OWNERSHIP
-------------	-------------------	---------------	------------------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

			of Section So(n) of the investment Company Act of 1940						
1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol <u>Eleven Biotherapeutics, Inc.</u> [EBIO]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
<u>HURLY STEPHEN A</u>				X	Director	10% Owner			
(Last) (First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year)	- x	Officer (give title below)	Other (specify below)			
C/O ELEVEN BIOTHERAPEUTICS, INC.			09/20/2016		President and CEO				
215 FIRST STR	EET, SUITE 400								
(Street) CAMBRIDGE	МА	02142	- 4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	/idual or Joint/Group Filin Form filed by One Rep Form filed by More tha	porting Person			
(City)	(State)	(Zip)	-		Person				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11311.4)
Common Stock	09/20/2016		A		398,031	Α	(1)	398,031	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative Expiration Date C Securities (Month/Day/Year) U Acquired (A)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option	\$3.37	09/20/2016		A		350,000		(2)	09/19/2026	Common Stock	350,000	\$0	350,000	D	

Explanation of Responses:

1. The reporting person acquired 398,031 shares of issuer common stock in exchange for a 9.9175% interest in Viventia Bio Inc. pursuant to the issuer's purchase of all of the outstanding capital stock of Viventia Bio Inc. on September 20, 2016. Of the 398,031 shares issued to the reporting person in the transaction, 39,803 shares are currently being held in escrow and are subject to forfeiture during the 15-month period following the transaction to satisfy claims arising as a result of Viventia Bio Inc.'s or the reporting person's breach of any of its or his representations, warranties or covenants in the share purchase agreement. 2, 25% of the shares subject to such option shall vest on the first anniversary of the date of grant of the option and an additional 6.25% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until the fourth anniversary of the date of grant of the option.

Remarks:

<u>/s/ S</u>	<u>tephen A.</u>	Hurly	

09/22/2016

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).